FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Anticoagulation in obese patients: challenges and strategies
2022PDF: 522HTML: 302XML: 185 -
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
515PDF: 14 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
909PDF: 118HTML: 121Supplementary: 78Appendix: 79 -
PO53 | Effectiveness and safety of DOACS in patients with renal transplantation A. Ierardi, A. Strangio, M. Leotta, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU Renato Dulbecco, Catanzaro, Italy
637PDF: 17 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
642PDF: 21 -
CO-57 | NXT007 PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITH OR WITHOUT FACTOR VIII INHIBITORS: COMBINED ANALYSIS OF TWO PHASE I/II MULTIPLE-ASCENDING-DOSE STUDIES M.E. Mancuso1|2, M. Shima3, J.M. Staber4, Y.C. Chen5, F.J. López-Jaime6, M.C. Shen7, G. Ventriglia8, M. Takeyama9, C. Schmitt8, Y.S. Park10, A. Kiialainen8, N. Mizuno11, M. Niggli8, T. Miyake11, D. Matino12, T. Saito11, V. Jiménez-Yuste13, R. Kobayashi11, D. Hart14, K. Nogami15 | 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy; 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 3Thrombosis and Hemostasis Research Center, Nara Medical University, Kashihara, Nara, Japan; 4Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, USA; 5Hemophilia Care and Research Center, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; 6Servicio de Hematología, Hospital Universitario Regional de Málaga / Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; 7Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 8F. Hoffmann-La Roche Ltd, Basel, Switzerland; 9Division of Hemophilia, National Hospital Organization, Osaka National Hospital, Osaka, Japan; 10Department of Pediatrics, Kyung Hee University Hospital at Gangdong, Seoul, South Korea; 11Chugai Pharmaceutical Co., Ltd, Tokyo, Japan; 12McMaster University, Hamilton, Ontario, Canada; 13La Paz University Hospital-IdiPAZ, Autónoma University, Madrid, Spain; 14Roche Products Ltd, Welwyn Garden City, UK; 15Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan
22PDF: 14 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
625PDF: 23 -
PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy
839PDF: 14 -
CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma; 4IRCCS Neuromed, Pozzilli, Italy
749PDF: 24 -
PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione, Santobono Pausilipon Children Hospital, AORN, Napoli, Italy
565PDF: 22 -
CO-24 | BALANCING BLEEDING AND THROMBOSIS: SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH HEMOPHILIA UNDERGOING MAJOR SURGERY S. Bergonzi1|2|3, G. Murante1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda3|4, R. Pastorino3|4, F. Bocchi3|4, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, University of Turin, Italy
25PDF: 9 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
568PDF: 12 -
PO28 | Long term effectiveness and safety of venous thromboembolism with fondaparinux: data from the start registry I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma, Roma; 4IRCCS NeuRomad, Pozzilli, Italy
633PDF: 12 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
497PDF: 123 -
PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, D. Menichelli1, T. Brogi2, S. Marucci2, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
646PDF: 25 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1443PDF: 303HTML: 201Supplementary: 102 -
OC06 | PRIMARY THROMBOPROPHYLAXIS IN ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA UNDERGOING SYSTEMIC ANTICANCER TREATMENT: A CANCER-CENTER COHORT STUDY ON CLINICAL PRACTICE AND OUTCOMES F. Haque1|2, A. Adekeye1|2, Z. Mohtashim2, K. Page1, M. Goodman1, A. Maraveyas 1|2 | 1Hull University Teaching Hospital NHS Trust, UK; 2Hull York Medical School, UK
471PDF: 104 -
CO-23 | PERIOPERATIVE MANAGEMENT OF MILD-TO-MODERATE HEMOPHILIA: A COMPARATIVE STUDY OF EXTENDED HALF-LIFE VERSUS STANDARD HALF-LIFE CONCENTRATES ON CLINICAL OUTCOMES AND FACTOR CONSUMPTION M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, S. Bergonzi1|2|3, G. Murante1|2|3, A. Valpreda4, R. Pastorino1|3, F. Bocchi1|3, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, University of Turin, Italy
27PDF: 9 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
458PDF: 98 -
PO31 | Comparative analysis of anticoagulant therapy in patients over 90 years old: vitamin K antagonists versus direct oral anticoagulants G. Sottilotta1, P. Arrigo2, S. Cuzzocrea1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie, Emostasi e Trombosi, Grande Ospedale Metropolitano di Reggio Calabria; 2Associazione Italiana Pazienti Anticoagulati, Sezione di Reggio Calabria; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
590PDF: 15 -
CO03 | Early discharge and home treatment of low-risk pulmonary embolism: a cohort study E. Ruggeri1, L. Vulcano1, W. Ageno2, F. Cortellaro3, M.P. Donadini3,4 | 1Scuola di Medicina, Università degli Studi dell’Insubria, Varese; 2Dipartimento di Medicina, Università degli Studi di Padova; 3Pronto Soccorso e Medicina d’Urgenza, Ospedale di Circolo, ASST Sette Laghi, Varese; 4Dipartimento di Medicina e Chirurgia, Università degli Studi dell’Insubria, Varese, Italy
662PDF: 23 -
PO08 | Efficacy and safety of thromboprophylaxis in hospitalized hematological patients: a monocenter retrospective study S. Cordella1,2, V. Coluccio3, M. Luppi1, M. Marietta1 | 1Department of Medical and Surgical Sciences, Section of Hematology. University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena; 2Clinical and Experimental Medicine PhD Programme, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena; 3Department of Hematology, Unità Sanitaria Locale di Modena, Italy
569PDF: 15 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
639PDF: 18 -
CO-75 | ASSAY DISCREPANCY IN HEMOPHILIA A CARRIERS: CLINICAL AND GENETIC INSIGHTS M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia Treatment Center AOU Dulbecco, Catanzaro, Italy
22PDF: 14 -
CO-17 | EMBODIED SELF-MANAGEMENT IN HEMOPHILIA: PSYCHOSOMATIC EFFECTS OF A SUPERVISED PHYSICAL ACTIVITY PROGRAM F. Valeri1, M. Miniotti2, M.G. Bailon2, C. Dainese1, B. Bruno3, P. Leombruni2, A. Borchiellini1 | 1Regional Centre for Haemorrhagic and Thrombotic Disease, Hematology Division, AOU Città della Salute e della Scienza, Torino, Italy; 2Departement of Neurosciences Rita Levi Montalcini, University of Turin, Italy; 3Division of Hematology, AOU Città della Salute e della Scienza, Department of Molecular Biotechnology and Health sciences, University of Turin, Italy
19PDF: 6 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
485PDF: 127 -
CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study Chiara Cavallaro1,2, Paolo Santini1,2, Laura Leoni3, Carolina Mosoni1,2, Silvia D’Ambrosio1,2, Francesco Mancinetti1,2, Nicola Coletta1,2, Michela Iorio1,2, Angelo Porfidia1,2, Alessandro D’Errico1,2, Rosa Talerico1,2, Roberto Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Università Cattolica del Sacro Cuore, Rome; 3Vita-Salute University, San Raffaele Hospital IRCCS, Milan, Italy
662PDF: 26 -
CO-61 | REAL-WORLD IMPLEMENTATION OF GENE THERAPY FOR HEMOPHILIA: A SHARED PATHWAY AMONG HEALTHCARE AUTHORITY, SPECIALIST CENTERS AND PATIENT ORGANIZATIONS IN THE EMILIA-ROMAGNA REGION A. Coppola1, L. Valdrè2, C. Biasoli3, E. Ferri Grazzi4, E. Rozzi5, M. Volta5, R. Giroldini6, A. Tagliaferri1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SSD Malattie Emorragiche Congenite, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; 3SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche, AUSL Romagna, Ospedale Bufalini, Cesena, Italy; 4FEDRED, Federazione delle Associazioni Emofilici della Regione Emilia Romagna, Italy; 5Servizio Assistenza Ospedaliera, Malattie Rare, Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia Romagna, Italy; 6Area Governo del Farmaco e Dispositivi Medici, Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia Romagna, Italy
20PDF: 9 -
PO56 | Safety of anticoagulant treatment in patients with splanchnic vein thrombosis and history of portal hypertension-related bleeding R. Talerico1, S. Pellegrino1, A. Plessier2, F.R. Ponziani3, A. Porfidia1, F. Landi1, A. Gasbarrini3, R. Pola1, F. Santopaolo3 | 1Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 2Université de Paris, AP-HP, C, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVE. Centre de recherche sur l’inflammation, Inserm, Paris, France; 3Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
607PDF: 18 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
742PDF: 23 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
476PDF: 115 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
605PDF: 23 -
CO-60 | A TURNING POINT IN THE MANAGEMENT OF HEMOPHILIA B WITH INHIBITORS: OUTCOMES OF CONCIZUMAB PROPHYLAXIS IN TWO CHILDREN FROM EXPLORER10 G. Quintavalle1, A. Matichecchia1, M.I. Tassoni1, B.M. Roccon1, F. Riccardi1, R.P. Serra2, A. Tiri2, P. Bertolini2, A. Tagliaferri1, A. Coppola1 | 1Regional Hub Center for Hemophilia and Congenital Bleeding Disorders, University Hospital of Parma, Italy; 2Pediatric Hematology-Oncology Unit, University Hospital of Parma, Italy
23PDF: 11 -
Development of a shared decision-making tool for gene therapy in hemophilia A in Italy
919PDF: 131SUPPLEMENTARY MATERIAL: 78 -
OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION W.E. Berdel, C. Schwöppe, C. Brand, K. Hessling, A.F. Berdel, T. Kessler, G. Lenz, R.M. Mesters, C. Schliemann | Department of Medicine A, University Hospital, Muenster, Germany
461PDF: 97 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
548PDF: 17 -
PO81 | Direct oral anticoagulants in atypical site vein thrombosis: a single centre experience focused on cancer patients U. Mazzarelli1, A. Guida1, L. Agrelli1, M. Amato1, R. Guarrasi2, L. Santaniello2, C. Cardamone1, P. Vitale1, M. Triggiani1 | 1Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche UOC Clinica Immunologica e Reumatologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno; 2UOC Clinica Oncologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
630PDF: 21 -
Diagnosis and management of abnormal uterine bleeding in adolescence An expert Consensus Statement of SIGO (Italian Society of Gynecology and Obstetrics) and SISET (Italian Society for the Study of Hemostasis and Thrombosis)
2838PDF: 728 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
497PDF: 96 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
755PDF: 20 -
PO76 | Thrombosis associated with midline in autoimmune patient: a case report on the use of apixaban in a real-world setting M.V. Cherchi, M. Anedda, S. Che, M. Vacca, M. Caboni, M. Mantega | Department of Internal Medicine, ASL Sulcis, Italy
589PDF: 26 -
CO-50 | LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND BLEEDING DISORDERS: A SINGLE-CENTER EXPERIENCE B.M. Roccon1, M.I. Tassoni1, G. Quintavalle1, G. Benatti2, F. Gurgoglione2, R. Rossi3, C. Cattabiani3, L. Vignali2, A. Tagliaferri1, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SSD Cardiologia Interventistica, Azienda Ospedaliero-Universitaria di Parma, Italy; 3Laboratorio di Coagulazione, UOC Patologia Clinica, Azienda Ospedaliero-Universitaria di Parma, Italy
23PDF: 11 -
PO93 | Use of DOACS in heart transplantation recipients T. Marrazzo1, A. Delle Femine1, C. Amarelli2, R. Albisinni3 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 2UOSD CCH dei Trapianti, Ospedale Monaldi Azienda dei Colli, Napoli; 3UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
738PDF: 17 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
436PDF: 96 -
CO-77 | PERINATAL MANAGEMENT IN WOMAN WITH MILD HEMOPHILIA B: A TWIN PREGNANCY CASE T. Martini1, B. Borsellino1|2, B. Pollio1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
23PDF: 10 -
CO-18 | PSYCHOMETRIC ASSESSMENT OF PATIENT REPORTED EXPERIENCES WITH ARTIFICIAL INTELLIGENCE TOOLS IN HEMOPHILIA CARE G. Sottilotta 1|2 , G. Praticò 1 , D. Megalizzi 1 , M. Hart 2 , C. Komar 2 , F. Luise 3 | 1 UOSD Centro Microcitemie - Servizio Emostasi e Trombosi. Grande Ospedale Metropolitano di Reggio Calabria, Italy; 2 Save One Life Inc., USA; 3 Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
23PDF: 8 -
Platelet distribution width is associated with cardiovascular mortality in an adult general population
3079PDF: 507Supplementary Material: 142 -
PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
499PDF: 109 -
CO-44 | EVALUATION OF THE DEVIATION BETWEEN PRESCRIBED AND RECOMMENDED EMICIZUMAB DOSING IN PATIENTS WITH CONGENITAL HEMOPHILIA A A.C. Giuffrida1, S. Abeysinghe Gunawardhana1, S. Amato2, F. Casoli2, C. Recchi2, M. Saggioro2, E. Bonetti3, M. Bodini1, G. Poli2 | 1Centro Emofilia, UOC Medicina Trasfusionale, AOUI Verona, Italy; 2UOC Laboratorio Analisi, AOUI Verona, Italy; 3UOC Oncoematologia Pediatrica, AOUI Verona, Italy
25PDF: 9 -
PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer L. Jr Valletta, C. De Luca, M. Aversano, C. Caputo, E. Cimino, P. Conca, A. Tufano, M.D. Di Minno | AOU Federico II Napoli, Italy
562PDF: 16 -
The use of creatine and the development of deep vein thrombosis. A scoping review
9038PDF: 807Supplementary: 210 -
CO37 | Assessment of clotting factor activity and sterility in thawed fresh frozen plasma supplied to helicopter emergency medical services for prehospital transfusion D. Romeo1, M. Marchetti1,2, M. Testa1, A. Motta1, P. Gomez-Rosas1, G. Ravasio1, F. Daminelli3, L. Barcella1, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine Department, Hospital Papa Giovanni XXIII, Bergamo; 2School of Medicine and Surgery, University Milano Bicocca, Milan; 3Anesthesia and Resuscitation Department, Hospital Papa Giovanni XXIII, Bergamo, Italy
675PDF: 18 -
PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
658PDF: 26 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
427PDF: 88 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
615PDF: 20 -
CO-38 | CALIBRATION OF HUMAN COAGULATION FACTOR VIII IN NOVEL QUALITY CONTROL MATERIALS: A COLLABORATIVE STUDY G. Gullifa1, A. Carocci1, C. Albertini1|2, L. Luchetti1, M.T. Pasquino1, M. Simeoni1, L. Mandarino1, C. Adriano1|3, R. Risoluti3, S. Massimi1 | 1Centro Nazionale per il Controllo e la Valutazione dei Farmaci, Istituto Superiore di Sanità, Roma, Italy; 2Centro Nazionale Sangue, Istituto Superiore di Sanità, Roma, Italy; 3Sapienza Università di Roma, Italy
20PDF: 10 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
792PDF: 17 -
CO-64 | REAPPRAISAL OF DESMOPRESSIN FOR MANAGEMENT OF MILD/MODERATE VON WILLEBRAND DISEASE: RESULTS OF A RETROSPECTIVE ANALYSIS IN 127 ITALIAN PATIENTS SUGGEST FURTHER ORGANIZATION OF PROSPECTIVE OBSERVATIONAL STUDIES TO PREDICT DESMOPRESSIN FAILURE WITH IMMEDIATE VWF CONCENTRATES REQUIREMENT A.B. Federici1, G. Castaman2 | 1Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Polo Didattico Università di Milano, Italy; 2Centro Emofilia e Malattie Emorragiche Regione Toscana, Ospedale Careggi, Firenze, Italy
26PDF: 10 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
555PDF: 21 -
BEST-06 | OPTIMIZING LABORATORY MONITORING OF EFANESOCTOCOG ALFA: IMPACT OF APTT REAGENTS AND CHROMOGENIC ASSAYS ON DIAGNOSTIC ACCURACY A. Strangio, A. Ierardi, M. Leotta, L.C. Elia, M. Falbo, C. Condina, G. Procopio, R.C. Santoro | Hemophilia Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
67PDF: 10 -
PO59 | Efficacy and safety of different anticoagulant treatment regimens for isolated internal jugular vein thrombosis: a case series A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, S. Marucci2, D. Menichelli1, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
688PDF: 30 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
444PDF: 94 -
PO20 | Impact of endovascular treatment on functional outcome in ischemic stroke: a real-world retrospective study M.G. Mosconi1, G. Maraziti1, M. Paciaroni2, J. Fagotti3, V. Caso1 | 1Azienda Ospedaliera di Perugia; 2Università degli Studi di Ferrara; 3Ospedale San Giovanni Battista, Foligno (PG), Italy
652PDF: 16 -
CO-33 | REAL-WORLD EXPERIENCE WITH MARSTACIMAB PROPHYLAXIS IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS AND ADVANCED HEMOPHILIC ARTHROPATHY A. Casson1, I. Ricca1, A. Barchieri1, G. Guido1, M. Tucciarone1, P. Ocello1, C. Francisco2, P. Abrate2, G. Delios1 | 1Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Torino, Italy; 2SC Farmacia Ospedaliera ASL TO4, Ivrea, Torino, Italy
22PDF: 8 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
473PDF: 109 -
CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro1, S. Akula1, B. Pollio2, I. Ricca2, T. Martini2, J. Agnelli Giacchello3, P. Sciancalepore3, R. Santi3, A. Follenzi1,3, S. Merlin1 | 1Università del Piemonte Orientale, Health Sciences, Novara; 2A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
636PDF: 15 -
PO07 | PLATELET INHIBITION BY THE NOVEL NITRIC OXIDE-DONOR NITROSOOXYPROPANOL M. Lindkvist, J. Jakobsson, F. Lynfeldt, B. Sandberg, K. Fransén, K. Nilsson, M. Grenegård | Cardiovascular Research Centre, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
431PDF: 103 -
PO15 | Venous thromboembolism risk associated with midline catheters and peripherally inserted central catheters: a systematic review and meta-analysis D. Santagata1, F. Subri1, F. Dentali1,2, M.P. Donadini1, I. Giarretta2 | 1Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como; 2Department of Internal Medicine, Ospedale di Circolo and Fondazione Macchi, Varese, Italy
567PDF: 17 -
CO-27 | INNOVATIVE USE OF EPTACOG BETA TO TREAT ACUTE ELBOW HEMARTHROSIS IN A PEDIATRIC PATIENT WITH HEMOPHILIA B AND A HISTORY OF INHIBITORS, UNDERGOING SECONDARY PROPHYLAXIS WITH CONCIZUMAB L. Laterza1, P. Giordano2, G. Lassandro2 | 1University of Bari "Aldo Moro", Interdisciplinary Department of Medicine, Bari, Italy; 2Pediatric Haemophilia Center-AOUC Pol. Giovanni XXXIII, University of Bari “Aldo Moro”, Bari, Italy
24PDF: 12
1 - 84 of 84 items
